GlassScriptPhysician profile
Elizabeth H Blake
NPI 1295152908
$1,640.63
in general payments reported to CMS, 2019-2025
24 companies · $784 in 2025
The $784 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $78.85 · 2023: $448 · 2024: $226 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.23 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.20 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $107.29 | 2022-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $100.90 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $98.29 | 2022-2025 | Qelbree, Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.10 | 2023-2025 | Relistor, Xifaxan, Trulance |
| Amgen INC. | $72.72 | 2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $70.67 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $67.42 | 2023-2025 | Farxiga, Airsupra |
| Sunovion Pharmaceuticals INC. | $66.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.05 | 2023-2025 | Trintellix |
| Novo Nordisk INC | $63.22 | 2024-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $59.80 | 2025 | Ibsrela |
| Abbott Laboratories | $43.67 | 2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $41.13 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $38.64 | 2025 | Ohtuvayre |
| Dexcom, INC. | $37.95 | 2023-2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $34.40 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $25.15 | 2024 | Fanapt, Hetlioz |
| Insulet Corporation | $25.08 | 2023 | Omnipod |
| Pfizer INC. | $20.06 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.56 | 2025 | |
| Esperion Therapeutics, INC. | $14.91 | 2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $13.97 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.